Crossmark

Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

Crossref DOI link: https://doi.org/10.1186/s40814-021-00873-5

Published Online: 2021-07-02

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sera, Valerie A.

Stevens, Ann E.

Song, Howard K.

Rodriguez, Victor M.

Tibayan, Frederick A.

Treggiari, Miriam M. https://orcid.org/0000-0003-4639-3682
Funding

Funding for this research was provided by:

Baxalta/Baxalta/Takeda (H13-26243)
License Information

Text and Data Mining valid from 2021-07-02

Version of Record valid from 2021-07-02
More Information

Article History

Received: 30 March 2021

Accepted: 21 June 2021

First Online: 2 July 2021

Declarations

:

: The study protocol was approved by the Institutional Review Board. Patients were enrolled in the trial after providing written informed consent preoperatively.

: Not applicable

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below